1. Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease
- Author
-
Weimin Yao, Biao Liang, Yong-jian Xu, Lizhen Zeng, Xiongbin Li, Xiangyan Zhang, Yan Chen, Xiwei Hu, Lingshan Zeng, Pixin Ran, Bin Hu, Nanshan Zhong, Gang Chen, Qianli Ma, Jia Tian, Xiaodan Zhu, Rongchang Zhi, Jianping Zhao, Chunxue Bai, Weishu Ye, Ying Li, Yumin Zhou, Fenglei Li, Shengming Liu, Guoping Hu, Liping Wei, Juan Du, Shuqing Yu, Minjing Li, Zhe Shi, Ping Huang, Xiaochen Li, Jinping Zheng, Ronghuan Yu, Changzheng Wang, Xitao Ma, Changxiu Ye, Dongxing Zhao, Changli Yang, Canmao Xie, Wei-jie Guan, Yinhuan Li, Tao Chen, Xiufang Du, Shuyun Chen, Xiangwen Luo, Yingxiang Lin, Hui Tan, Xianwei Ye, Bingwen He, and Jianping Gui
- Subjects
Male ,medicine.medical_specialty ,medicine.drug_class ,Placebo ,law.invention ,03 medical and health sciences ,Pulmonary Disease, Chronic Obstructive ,0302 clinical medicine ,Randomized controlled trial ,Double-Blind Method ,law ,Internal medicine ,Bronchodilator ,Forced Expiratory Volume ,Administration, Inhalation ,Clinical endpoint ,Medicine ,Humans ,030212 general & internal medicine ,Tiotropium Bromide ,Aged ,COPD ,business.industry ,General Medicine ,Tiotropium bromide ,Middle Aged ,medicine.disease ,Obstructive lung disease ,respiratory tract diseases ,Bronchodilator Agents ,030228 respiratory system ,Anesthesia ,Disease Progression ,Quality of Life ,Female ,business ,medicine.drug - Abstract
BackgroundPatients with mild or moderate chronic obstructive pulmonary disease (COPD) rarely receive medications, because they have few symptoms. We hypothesized that long-term use of tiotropium would improve lung function and ameliorate the decline in lung function in patients with mild or moderate COPD. MethodsIn a multicenter, randomized, double-blind, placebo-controlled trial that was conducted in China, we randomly assigned 841 patients with COPD of Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 1 (mild) or 2 (moderate) severity to receive a once-daily inhaled dose (18 μg) of tiotropium (419 patients) or matching placebo (422) for 2 years. The primary end point was the between-group difference in the change from baseline to 24 months in the forced expiratory volume in 1 second (FEV1) before bronchodilator use. Secondary end points included the between-group difference in the change from baseline to 24 months in the FEV1 after bronchodilator use and the between-group difference in...
- Published
- 2017